1000101163.jpg

1000101166.jpg

Give a nice but effective answer for this question

Reading File

Finding Sources

Here is the complete model answer for the entire exam paper:

MCQ Answers (Part I)

Q19. B) Albumin - In systemic circulation, highly acidic drugs (like warfarin, NSAIDs, phenytoin) are predominantly bound to albumin, which is the most abundant plasma protein and carries both acidic and basic drugs.

Q20. A) Prior to the "aging" of the phosphorylated enzyme - Pralidoxime works by regenerating (reactivating) acetylcholinesterase. Once the organophosphate-enzyme complex undergoes "aging" (irreversible conformational change), pralidoxime becomes ineffective.

Section II - Structured Long Questions

Question 1: Organophosphate Poisoning (10 Marks)

a) Diagnosis and Molecular Mechanism of Toxicity (3 Marks)

Diagnosis: Acute Organophosphate (OP) Poisoning

The classic triad of:

Miosis (pinpoint pupils)
Excessive secretions (salivation, lacrimation, vomiting, urination)
Bradycardia + hypotension

...combined with garlic odor (characteristic of OP compounds), muscle fasciculations, and a history of pesticide exposure without PPE confirms this diagnosis. These features represent a full cholinergic crisis.

Exact Molecular Mechanism:

Organophosphates are irreversible inhibitors of the enzyme acetylcholinesterase (AChE). They phosphorylate the serine hydroxyl group at the active site of AChE (within the serine-glutamate-histidine catalytic triad). This prevents AChE from breaking down acetylcholine (ACh).

The consequence is accumulation of ACh at all cholinergic synapses:

Muscarinic receptors (smooth muscle, glands, heart): SLUDGE - Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis + bradycardia, bronchospasm, miosis
Nicotinic receptors (NMJ, autonomic ganglia): Muscle fasciculations, weakness, paralysis
CNS: Seizures, coma

b) Pharmacological Management - Mechanism of Action and Clinical End-Points (4 Marks)

Step 1 - Secure the airway, remove the patient from the source, remove contaminated clothing.

Primary Life-Saving Drug: ATROPINE

Mechanism of Action: Atropine is a competitive antagonist at muscarinic receptors (M1, M2, M3). It does NOT reverse nicotinic effects or the underlying enzyme inhibition, but it blocks the downstream effects of accumulated ACh at muscarinic sites.

Dosing: Start with 2-4 mg IV bolus, then double the dose every 5-10 minutes until atropinization is achieved.

Clinical End-Points of Adequate Atropinization:

Drying of secretions (dry mouth, dry skin, clear lungs)
Heart rate >80 bpm
Systolic BP >80 mmHg
Pupils: mydriasis (pupil size is NOT the primary endpoint)

Note: Atropine does NOT correct muscle fasciculations or weakness because these are nicotinic effects.

Step 2 - Pralidoxime (2-PAM) / Oxime Therapy

Mechanism: Pralidoxime is a nucleophile (pyridinium aldoxime) that attacks the phosphorus atom of the organophosphate-AChE conjugate. It causes a conformational change, releases the organophosphate from the enzyme, and regenerates active AChE. This addresses both muscarinic AND nicotinic effects.

Dose: 1 g IV, repeated every 3-4 hours, or as a continuous infusion at 250-400 mg/hour.

Critical: Pralidoxime must be given before enzyme aging occurs - ideally within 24-48 hours of exposure.

c) Enzyme "Aging" and Its Clinical Impact (3 Marks)

What is "Aging"?

Aging is the irreversible conformational change that occurs when the organophosphate-AChE complex is allowed to persist over time. After initial phosphorylation of the serine active site, the organophosphate undergoes a secondary chemical change (de-alkylation) that strengthens the bond between the OP compound and the enzyme, making it permanently inactivated - no longer susceptible to nucleophilic attack by oximes.

Time to Aging:

Varies by agent (e.g., soman ages within minutes; parathion takes hours to days)
Most common agricultural OP insecticides: aging occurs over 24-48 hours

Clinical Impact:

Once aging has occurred, pralidoxime is completely ineffective - it cannot cleave the strengthened phosphonate bond
The patient becomes dependent only on atropine for symptomatic control and on synthesis of new AChE for recovery (which takes weeks)
This is why pralidoxime must be administered as early as possible after OP exposure
If a patient presents >48 hours after exposure, oximes should generally NOT be used (risk of oxime toxicity without benefit)

Question 2: Propranolol + Aspirin in Bronchial Asthma (10 Marks)

a) Propranolol: Mechanism and Why It Caused Acute Exacerbation (3 Marks)

Propranolol is a non-selective beta-adrenergic receptor antagonist (blocks both β1 and β2 receptors). It is used here for migraine prophylaxis.

Normal physiology: Sympathetic stimulation of β2 receptors in bronchial smooth muscle causes bronchodilation (relaxation). Endogenous catecholamines (adrenaline) keep the airways dilated, especially during stress/exercise.

Mechanism of Exacerbation: By blocking β2 receptors in bronchial smooth muscle, propranolol:

Removes the sympathetic bronchodilatory tone
Leaves parasympathetic (cholinergic) bronchoconstriction unopposed
Results in bronchoconstriction, increased airway resistance, and bronchospasm

In a patient with pre-existing asthma, where airways are already hyperreactive, this β2 blockade precipitates severe, life-threatening bronchospasm.

Propranolol is absolutely contraindicated in bronchial asthma. If a beta-blocker is required in such patients, a cardioselective β1 blocker (e.g., metoprolol, atenolol) should be used with extreme caution.

b) Aspirin: Mechanism and Why It Caused Acute Exacerbation (3 Marks)

This is called Aspirin-Exacerbated Respiratory Disease (AERD) or "Samter's triad."

Normal Arachidonic Acid Metabolism: Arachidonic acid is metabolized via two pathways:

COX pathway → Prostaglandins (especially PGE2, which inhibits 5-lipoxygenase and has a bronchodilatory/protective role)
5-Lipoxygenase (5-LOX) pathway → Leukotrienes (LTC4, LTD4, LTE4 - potent bronchoconstrictors)

Mechanism of Aspirin-Induced Exacerbation:

Aspirin irreversibly inhibits COX-1 (and COX-2)
This reduces PGE2 production
PGE2 normally inhibits 5-LOX - with less PGE2, this inhibition is lifted
Arachidonic acid is shunted to the 5-LOX pathway
Massive increase in leukotriene (LTC4, LTD4) production
Leukotrienes cause severe bronchoconstriction, airway edema, and mucus hypersecretion

This explains why leukotriene receptor antagonists (montelukast, zafirlukast) can prevent and treat aspirin-exacerbated asthma.

c) Four Therapeutic Uses of Propranolol (2 Marks)

Hypertension (reduces cardiac output + renin release)
Angina pectoris (reduces myocardial O2 demand)
Cardiac arrhythmias (supraventricular tachycardia, AF rate control)
Migraine prophylaxis (mechanism not fully known - reduces vascular reactivity)
(Bonus: Thyrotoxicosis - controls sympathetic symptoms; essential tremor; pheochromocytoma - after alpha-blockade)

d) Two Therapeutic Uses + Two Side Effects of Aspirin (2 Marks)

Therapeutic Uses:

Antiplatelet - low-dose aspirin (75-100 mg) in secondary prevention of MI and ischemic stroke (irreversible inhibition of platelet COX-1 → reduced TXA2 → reduced platelet aggregation)
Analgesic/Antipyretic/Anti-inflammatory - moderate doses for fever, mild-to-moderate pain, rheumatic conditions

Side Effects:

Peptic ulcer disease - inhibition of COX-1 reduces gastroprotective PGE2 → decreased mucus and bicarbonate secretion, decreased mucosal blood flow → ulcer formation; can cause GI bleed
Reye's syndrome - in children with viral infections (aspirin should be avoided in children <12 years); characterized by acute liver failure + encephalopathy
(Bonus: Tinnitus/salicylism at high doses; aspirin-exacerbated respiratory disease; anticoagulant bleeding risk)

Section III - Short Notes (Reasoning Questions)

1. Why Non-Selective β-Blockers Are Avoided in Diabetes Mellitus

Non-selective β-blockers (e.g., propranolol) block both β1 and β2 receptors. In diabetic patients on insulin or sulfonylureas, this causes two major problems:

Masking of hypoglycemia symptoms: The sympathetically-mediated warning signs of hypoglycemia (tachycardia, palpitations, tremor) are mediated by β1/β2 receptors. β-blockers blunt these symptoms, so the patient does not recognize hypoglycemia - leading to unawareness of hypoglycemia, which can be fatal.
Prolonged hypoglycemia: Gluconeogenesis (hepatic glucose release in response to hypoglycemia) is partly mediated by β2 receptors. Blocking β2 delays recovery from hypoglycemia by impairing glycogenolysis and gluconeogenesis.
Diaphoresis (sweating) is a cholinergic response, so it is NOT masked - this remains the only warning sign.

If a β-blocker is needed in a diabetic, use a cardioselective β1-blocker (metoprolol, atenolol) with close glucose monitoring.

2. Why High Plasma Protein Binding Leads to Long Duration of Action

Drug in plasma exists in two forms:

Bound fraction (to albumin or other proteins) - pharmacologically inactive, cannot cross membranes, not filtered by kidneys, not metabolized
Free fraction - pharmacologically active

When a drug is highly protein-bound:

The bound drug acts as a reservoir/depot - slowly releasing free drug as the free fraction is eliminated
The drug is protected from hepatic metabolism (only free drug is metabolized)
The drug is not renally filtered (bound drug is too large to cross glomerular membrane)
This results in a large apparent volume of distribution and a prolonged elimination half-life

Result: The drug persists in the body for a much longer time, giving it a long duration of action.

Example: Warfarin (99% protein-bound), phenytoin (~90%).

3. Why Succinylcholine Is Contraindicated in Burns

Succinylcholine is a depolarizing neuromuscular blocking agent that acts as an ACh agonist at nicotinic receptors (NMJ), causing sustained depolarization and paralysis.

Normal: Succinylcholine causes a brief rise in serum K+ (~0.5 mEq/L) as K+ flows out during depolarization - harmless in healthy patients.

In Burn Patients (after 24-48 hours): Following burns, there is proliferation (upregulation) of extrajunctional ACh receptors (fetal-type/alpha-7 receptors) throughout the entire muscle membrane (not just the NMJ). These are expressed at sites that do not normally have high receptor density.

When succinylcholine is given:

It activates all these upregulated extrajunctional receptors
Causes massive, diffuse membrane depolarization across the entire muscle
Results in massive efflux of K+ from the entire muscle
Serum K+ can rise by 5-13 mEq/L, causing life-threatening hyperkalemia → cardiac arrest

This upregulation begins 24-48 hours after the burn and persists for up to 2 years (until full healing/recovery).

Safe alternative: Non-depolarizing agents (vecuronium, rocuronium).

4. Why Pralidoxime Is NOT Used in Carbamate Poisoning

Carbamates (e.g., physostigmine, neostigmine) also inhibit AChE - but the carbamate-AChE bond is spontaneously reversible (carbamylation is hydrolyzed within 30-60 minutes).

Pralidoxime works by attacking the phosphorus of the OP-AChE complex
In carbamate poisoning, the carbamate-AChE bond undergoes spontaneous hydrolysis - enzyme activity recovers on its own
More importantly, pralidoxime with carbamates can actually form a stable inhibited complex (pralidoxime-carbamylated AChE complex), paradoxically worsening cholinesterase inhibition
Aging does not occur with carbamates
Treatment is therefore atropine alone (for symptomatic control) and supportive care

5. NSAIDs Cause Peptic Ulcer - Explanation

NSAIDs (including aspirin) cause peptic ulcers through two mechanisms:

A. Systemic (Main Mechanism): NSAIDs inhibit COX-1 (constitutively expressed in the gastric mucosa). COX-1 is responsible for producing prostaglandins (especially PGE2 and PGI2), which:

Stimulate mucus and bicarbonate secretion (protective barrier)
Maintain mucosal blood flow
Inhibit gastric acid secretion

When COX-1 is inhibited:

Mucus and bicarbonate production falls
Mucosal blood flow decreases
Acid secretion increases relatively
Result: Gastric mucosal breakdown → erosion → ulcer

B. Local (Direct Irritant): NSAIDs (especially aspirin) are weak acids. In the acidic gastric environment, they become lipid-soluble and penetrate gastric mucosal cells directly, causing local injury.

Management: Co-prescribe proton pump inhibitors (PPIs) or use COX-2 selective inhibitors (which spare COX-1 and gastric PGs), or misoprostol (a synthetic PGE1 analogue to replace mucosal PGs).

Section IV - Short Notes (Applied)

Q1: 28-Year-Old Female on TB DOTS + OCP → Missed Period / Pregnancy

a) Drug Responsible

Rifampicin is the drug responsible for the OCP failure.

b) Pharmacokinetic Mechanism

Rifampicin is a potent inducer of cytochrome P450 (CYP3A4) enzyme (and also P-glycoprotein) in the liver and gut wall.

Combined oral contraceptive pills (OCPs) contain estrogen (ethinyl estradiol) and progestins, which are metabolized by CYP3A4.

When rifampicin induces CYP3A4:

The metabolism of estrogen and progestin is greatly accelerated
Their plasma concentrations fall significantly (reduced bioavailability and increased clearance)
The OCP fails to suppress ovulation
Result: Contraceptive failure → unintended pregnancy

c) Alternative Contraceptive Advice

Barrier methods (condom + diaphragm) - most reliable during TB treatment
Intrauterine device (IUD/copper-T) - not affected by drug metabolism; highly effective
Depot-medroxyprogesterone acetate (injectable) - higher hormone levels may overcome some induction (though still not recommended as sole method)
Increase the OCP dose (at least 50 mcg ethinyl estradiol) - partially compensates, but still not ideal
The standard advice is to use barrier contraception for the entire duration of TB therapy + 4 weeks after stopping rifampicin

Q2: Anaphylactic Shock after Bee Sting

a) Drug of Choice

Adrenaline (Epinephrine) - administered intramuscularly into the anterolateral thigh (0.5 mg of 1:1000 in adults; 0.01 mg/kg in children). IM is preferred over SC for faster absorption in shock.

b) Mechanism by Which Epinephrine Reverses Bronchospasm and Hypotension

α1-adrenergic receptor activation:

Causes vasoconstriction of peripheral arterioles → increases systemic vascular resistance → reverses hypotension
Reduces angioedema by decreasing vascular permeability (counteracts histamine-mediated vasodilation and capillary leak)
Reduces mucosal edema (critical for laryngeal edema)

β2-adrenergic receptor activation:

Causes bronchial smooth muscle relaxation → bronchodilation → reverses bronchospasm
Inhibits mast cell and basophil degranulation → reduces further release of histamine, leukotrienes, and other mediators

β1-adrenergic receptor activation:

Increases heart rate and cardiac contractility → improves cardiac output → further supports blood pressure

c) Why Noradrenaline Is NOT Suitable Here

Noradrenaline (norepinephrine) acts on α1 and β1 receptors, but has minimal β2 activity.

Therefore, noradrenaline:

Cannot reverse bronchospasm (lacks effective β2 bronchodilation)
Does NOT inhibit mast cell mediator release
Causes reflex bradycardia (via baroreceptors activated by profound vasoconstriction, mediated through vagal tone) → worsens hypoperfusion
Does not address the full pathophysiology of anaphylaxis (bronchospasm, edema, mediator release)

Epinephrine uniquely provides all three components needed (α1 + β1 + β2), making it the only first-line agent in anaphylaxis.

Q3: Allopurinol 300 mg for Acute Gout → Pain Worsened Next Day

a) Why Did Allopurinol Aggravate the Acute Attack?

Allopurinol is a xanthine oxidase inhibitor used for chronic gout prevention. During an acute attack, starting allopurinol causes a sudden drop in serum uric acid levels.

This rapid change in urate concentration causes mobilization of urate crystals from joints and soft tissues into the synovial fluid. These liberated crystals trigger a fresh acute inflammatory response (neutrophil recruitment, cytokine release) that worsens the acute attack.

Principle: Allopurinol should NEVER be started during an acute gout attack. It should be initiated 2-4 weeks after the acute attack resolves, under the cover of colchicine or NSAIDs to prevent this rebound.

b) Mechanism of Allopurinol in Chronic Gout

Allopurinol is a purine analogue and a competitive inhibitor of xanthine oxidase (the enzyme that catalyzes the last two steps in uric acid biosynthesis: hypoxanthine → xanthine → uric acid).

It is also converted to alloxanthine (oxypurinol) by xanthine oxidase, which then becomes a suicide inhibitor (irreversible) of the enzyme
Result: Accumulation of hypoxanthine and xanthine (more soluble than urate) and reduction in serum and urinary uric acid → dissolution of tophi, prevention of gouty arthritis and urate nephropathy

c) Cellular Target of Colchicine in Relieving Acute Pain

Colchicine binds to tubulin (specifically the αβ-tubulin dimer) and inhibits microtubule polymerization.

This prevents:

Neutrophil migration into the joint (chemotaxis requires intact microtubules)
Phagocytosis of urate crystals by neutrophils (requires cytoskeletal remodeling)
Release of inflammatory mediators (lysosomal enzymes, IL-1β, prostaglandins)

Result: Acute gouty inflammation is aborted without affecting uric acid levels.

Q4: Primary Open-Angle Glaucoma (POAG) with IOP 28 mmHg

a) Classification of Drugs Used in Treatment

Class	Examples	Mechanism
Prostaglandin analogues	Latanoprost, bimatoprost, travoprost	Increase uveoscleral outflow
Beta-blockers (topical)	Timolol, betaxolol	Reduce aqueous humour production
Alpha-2 agonists	Brimonidine, apraclonidine	Reduce production + increase outflow
Carbonic anhydrase inhibitors	Dorzolamide (topical), acetazolamide (oral)	Reduce aqueous humour production
Miotics (cholinergics)	Pilocarpine	Increase trabecular outflow
Rho-kinase inhibitors	Netarsudil	Increase trabecular outflow

b) Mechanism by Which Latanoprost and Timolol Reduce IOP

Latanoprost (Prostaglandin F2α analogue):

Binds to FP (prostaglandin F) receptors on ciliary body smooth muscle and scleral tissues
Causes remodeling of the extracellular matrix in the uveoscleral pathway (increased expression of matrix metalloproteinases → breakdown of collagen in ciliary muscle)
This increases uveoscleral (unconventional) outflow of aqueous humour
Applied once daily (at night); reduces IOP by ~25-33%

Timolol (Non-selective β-blocker, topical):

Blocks β1 and β2 receptors on the non-pigmented ciliary epithelium
Reduces cyclic AMP (cAMP) production in the epithelium (since β receptors normally activate adenylyl cyclase)
This decreases active transport of Na+/HCO3- into the posterior chamber → reduces aqueous humour secretion/production by ~25-50%
Applied twice daily; excellent for daytime IOP control; minimal effect during sleep (when aqueous production is already low)

Section V - Short Notes (25 Marks)

1. Differences Between Zero-Order and First-Order Kinetics

Parameter	Zero-Order Kinetics	First-Order Kinetics
Definition	A constant amount of drug is eliminated per unit time	A constant fraction/percentage of drug is eliminated per unit time
Rate of elimination	Independent of drug concentration	Directly proportional to drug concentration
Half-life	Variable - increases as concentration rises	Constant regardless of concentration
Dose-concentration relationship	Non-linear (small dose change → disproportionate rise in plasma level)	Linear (predictable)
Saturation	Enzymes/transporters are saturated	Enzymes/transporters are NOT saturated (ample capacity)
Examples	Alcohol (ethanol), phenytoin (at toxic doses), aspirin (at high doses), warfarin (at high doses)	Most drugs at therapeutic doses (e.g., penicillin, atenolol, most standard medications)
Clinical danger	Dangerous - small dose increases can lead to toxic accumulation	Predictable and safe
Graph (plasma conc. vs time)	Straight line (linear decay)	Exponential curve (log-linear decay)

Key concept: Zero-order kinetics occurs when enzyme capacity is exceeded (Vmax is reached). The elimination rate becomes constant = Vmax/Km constant.

2. Adverse Effects of Alpha-Blockers

Alpha-1 blockers (e.g., prazosin, doxazosin, tamsulosin) and non-selective alpha-blockers (phentolamine):

Cardiovascular:

First-dose hypotension and syncope (especially with prazosin) - due to sudden vasodilation; advise to take first dose at bedtime
Reflex tachycardia - from vasodilation-induced baroreceptor activation (more with non-selective agents)
Orthostatic (postural) hypotension - dizziness on standing

Nasal/Upper Airway:

Nasal stuffiness/congestion - nasal mucosal vasodilation

CNS:

Dizziness, headache, drowsiness

Genitourinary:

Retrograde ejaculation (especially tamsulosin, which is uroselective α1A blocker)

Metabolic (non-selective alpha-blockers like phentolamine):

Tachycardia, arrhythmias (β receptors unmasked)

Specific to alpha-2 blockers (e.g., yohimbine):

Anxiety, hypertension, tremor

3. Agonist and Antagonist Acting on 5-HT System and Their Therapeutic Uses

5-HT (Serotonin) System Overview: Multiple receptor subtypes: 5-HT1, 5-HT2, 5-HT3, 5-HT4, etc.

AGONISTS:

Drug	Receptor	Therapeutic Use
Sumatriptan (and triptans)	5-HT1B/1D agonist	Acute migraine and cluster headache (causes cranial vasoconstriction + inhibits CGRP release)
Buspirone	5-HT1A partial agonist	Generalized anxiety disorder (non-benzodiazepine anxiolytic)
Metoclopramide	5-HT4 agonist	Prokinetic - gastroparesis, GERD, nausea (stimulates gastric motility)
Cisapride	5-HT4 agonist	Gastroparesis (withdrawn due to QT prolongation)

ANTAGONISTS:

Drug	Receptor	Therapeutic Use
Ondansetron	5-HT3 antagonist	Chemotherapy/radiation-induced nausea and vomiting; post-operative nausea
Clozapine / Olanzapine	5-HT2A antagonist (+ D2)	Schizophrenia (atypical antipsychotic)
Cyproheptadine	5-HT2 antagonist	Allergic conditions, appetite stimulation, carcinoid syndrome
Methysergide	5-HT2 antagonist	Migraine prophylaxis (now rarely used - causes retroperitoneal fibrosis)

4. Mechanism of Action of Non-Depolarizing Blockers and Toxicity of Neuromuscular Blockers

Non-Depolarizing (Competitive) Blockers: (e.g., Vecuronium, Atracurium, Rocuronium, Pancuronium, d-Tubocurarine)

Mechanism:

These drugs are competitive antagonists at the nicotinic acetylcholine receptor (nAChR) at the NMJ
They bind to the alpha-subunits of the nAChR (at the ACh binding sites) without activating the channel
They block ACh from binding and prevent end-plate depolarization
Since there is no depolarization, there is no muscle contraction → flaccid paralysis
The block is competitive and reversible - can be reversed by increasing ACh (using anticholinesterases: neostigmine + atropine, or sugammadex for rocuronium/vecuronium)
Fasciculations do NOT occur (unlike succinylcholine)

Toxicity / Adverse Effects of Neuromuscular Blockers (General):

Effect	Mechanism
Prolonged apnea/paralysis	Overdose or pharmacogenomic variation (e.g., pseudocholinesterase deficiency with succinylcholine)
Histamine release (d-tubocurarine, atracurium)	Hypotension, bronchospasm, urticaria
Autonomic ganglia blockade (d-tubocurarine)	Hypotension
Vagal blockade (pancuronium)	Tachycardia, hypertension
Hyperkalemia (succinylcholine in burns, denervation, crush injury)	Extrajunctional receptor upregulation → massive K+ release
Malignant hyperthermia (succinylcholine + volatile anesthetics)	Uncontrolled Ca2+ release from sarcoplasmic reticulum; treat with dantrolene
Increased IOP, ICP, intragastric pressure (succinylcholine)	Muscle fasciculations

5. Factors Modifying Drug Action

Drug action in a patient can be modified by the following factors:

A. Patient-Related Factors:

Age:
- Neonates/Infants: Immature liver enzymes, reduced plasma protein binding, increased BBB permeability, higher body water content
- Elderly: Reduced hepatic blood flow, decreased GFR, reduced albumin → higher free drug levels, prolonged drug action
Body weight/composition: Obese patients have larger volume of distribution for lipophilic drugs
Sex: Females have higher body fat %, different CYP450 enzyme activity, hormonal variations affecting drug metabolism
Genetic factors (Pharmacogenomics):
- Slow vs. fast acetylators (INH, hydralazine)
- Pseudocholinesterase deficiency (succinylcholine apnea)
- G6PD deficiency (hemolysis with primaquine, dapsone)
- CYP2D6 polymorphism (codeine metabolism)
Pregnancy: Increased plasma volume, altered CYP activity, potential teratogenicity, placental transfer to fetus
Disease states:
- Hepatic disease: Impaired drug metabolism → toxicity with hepatically metabolized drugs
- Renal disease: Accumulation of renally excreted drugs
- Thyroid disease: Altered drug metabolism rate (hyperthyroid = faster; hypothyroid = slower)
- Hypoalbuminemia: Increased free drug fraction → enhanced effect/toxicity

B. Drug-Related Factors:

Dose and dosage form: Higher dose, faster-release formulations → greater/faster effect
Route of administration: IV > IM > SC > oral (bioavailability and speed)
Time of administration: Chronopharmacology - some drugs are more effective or toxic at certain times of day

C. External Factors:

Drug interactions:
- Pharmacokinetic (enzyme induction/inhibition, protein binding displacement, altered absorption)
- Pharmacodynamic (synergism, antagonism)
Tolerance and tachyphylaxis: Reduced response with repeated drug use (e.g., morphine tolerance, nitrate tolerance)
Placebo effect and psychological factors
Diet and environment: Grapefruit juice inhibits CYP3A4; smoking induces CYP1A2; charcoal-grilled food induces drug metabolism

Sources: Katzung's Basic and Clinical Pharmacology 16e | Lippincott Illustrated Reviews: Pharmacology | Goodman & Gilman's Pharmacological Basis of Therapeutics | Tintinalli's Emergency Medicine | Rosen's Emergency Medicine

Opioid posing

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have excellent textbook-verified content to write a comprehensive answer on opioid poisoning.

Opioid Poisoning

Overview

Opioid poisoning (opioid toxidrome / overdose) is a life-threatening emergency caused by excessive stimulation of opioid receptors - most commonly the mu (μ) receptor - leading to profound CNS and respiratory depression.

Common causes: Heroin, morphine, fentanyl, methadone, oxycodone, codeine, pethidine; also buprenorphine in partial agonist overdose.

Opioid Receptor Types and Their Relevance

Receptor	Key Effects When Overstimulated
μ (Mu / MOP)	Analgesia, respiratory depression, euphoria, miosis, constipation, physical dependence
κ (Kappa / KOP)	Sedation, dysphoria, miosis, spinal analgesia
δ (Delta / DOP)	Analgesia, mood modulation

Opioid poisoning is primarily a μ-receptor excess syndrome.

Clinical Features - The "Opioid Toxidrome"

The classic triad to remember:

"Coma + Miosis + Respiratory Depression" = Opioid poisoning until proven otherwise

System	Features
CNS	Unconsciousness / deep coma, decreased GCS, drowsiness progressing to unresponsive state
Eyes	Bilateral pinpoint (miotic) pupils - hallmark sign; occurs due to μ and κ receptor stimulation of Edinger-Westphal nucleus
Respiratory	Slow, shallow breathing (bradypnea <12/min) → apnea; opioids depress the brainstem respiratory center's response to CO2 and hypoxia; this is the primary cause of death
Cardiovascular	Bradycardia, hypotension (especially with methadone - also prolongs QTc)
GI	Nausea, vomiting, decreased bowel sounds
Skin	Cyanosis (from hypoxia), cold clammy skin, track marks (IV drug use)
Neurological	Muscle flaccidity, absent gag reflex, seizures (with meperidine/tramadol - due to toxic metabolite normeperidine)

Important: Methadone and fentanyl overdose may require far higher and repeated doses of naloxone due to their potency and long half-lives.

Pathophysiology

Opioids bind to μ-receptors on brainstem respiratory neurons (pre-Bötzinger complex)
Receptor activation opens K+ channels (hyperpolarization) and inhibits voltage-gated Ca2+ channels → reduced neuronal firing
This suppresses the central respiratory drive → bradypnea → apnea → hypoxia → hypercapnia
Miosis: μ and κ receptor stimulation in the midbrain → Edinger-Westphal nucleus activation → pupillary constriction (paradoxical, since this is a "stimulatory" effect)
Euphoria: μ receptor activation increases dopamine release in the nucleus accumbens (mesolimbic reward pathway)

Diagnosis

Clinical - the classic triad is usually sufficient
Pulse oximetry: SpO2 < 90%, rising CO2 (end-tidal or ABG)
ABG: Respiratory acidosis (↑PaCO2, ↓pH, ↓PaO2)
Urine toxicology screen: Confirms opioid exposure (but does not change acute management)
ECG: Important for methadone (QTc prolongation → risk of Torsades de Pointes)
Blood glucose: Rule out hypoglycemia as a concurrent/alternative cause of coma

Diagnostic test and treatment combined: If naloxone is given and the patient wakes up and breathes - the diagnosis is confirmed.

Treatment

Step 1 - Immediate Resuscitation (ABC)

Airway: Head-tilt chin-lift / jaw thrust; suction secretions; insert oropharyngeal airway if unconscious
Breathing: Bag-valve mask ventilation with 100% O2 if respiratory rate < 10/min or SpO2 < 90%
Circulation: IV access, cardiac monitoring, IV fluids for hypotension

Step 2 - Antidote: NALOXONE (the definitive treatment)

Naloxone is a pure competitive opioid receptor antagonist (μ, κ, δ) with no agonist activity. It displaces opioids from receptors and rapidly reverses all features of poisoning.

Route	Dose	Onset
IV (preferred)	0.4-2 mg, repeat every 2-3 min as needed	1-2 minutes
IM	0.4-0.8 mg	3-5 minutes
Intranasal (IN)	2-4 mg per nostril (take-home kits)	Slightly slower than IM
Subcutaneous	0.4-0.8 mg	Slower, less reliable in shock

Key points for dosing:

Start with 0.4-0.8 mg IV and titrate upward
Repeat every 2-3 minutes if no response; up to 10 mg may be needed for fentanyl/synthetic opioids
Goal: Restore respiratory rate > 10/min and SpO2 > 92% - NOT full awakening (which precipitates withdrawal)
Half-life of naloxone is short (30-90 min) - much shorter than most opioids; patient may "re-narcotize" after naloxone wears off
For long-acting opioids (methadone, sustained-release morphine): naloxone infusion (IV drip at 2/3 of the effective bolus dose per hour) is required
If no response after 10 mg naloxone → reconsider the diagnosis (sedatives, benzodiazepines, hypoglycemia, head injury)

Step 3 - Supportive Care

Endotracheal intubation + mechanical ventilation if naloxone fails or patient remains apneic
Treat pulmonary edema (can occur after rapid naloxone reversal in hypoventilated patients - non-cardiogenic; manage with CPAP/oxygen)
Treat seizures (especially with meperidine/tramadol toxicity) with benzodiazepines
Methadone overdose: prolonged monitoring (24-72 hours), ECG monitoring, correct QTc

Opioid Withdrawal (for completeness)

When opioids are abruptly stopped in physically dependent patients, the opposite of the toxidrome occurs - hyperadrenergic state:

Feature	Description
Eyes	Mydriasis (dilated pupils), lacrimation, yawning
GI	Severe diarrhea, vomiting, cramping
CNS	Agitation, anxiety, insomnia, drug craving, dysphoria
Autonomic	Tachycardia, hypertension, sweating, piloerection ("gooseflesh")
Musculoskeletal	Muscle aches, restless legs

Treatment of withdrawal:

Methadone (full μ-agonist taper) or buprenorphine (partial μ-agonist) - the mainstay
Clonidine / Lofexidine - α2-agonist; suppresses the noradrenergic hyperactivity (autonomic symptoms) without opioid activity
Symptomatic: Loperamide for diarrhea, NSAIDs for muscle aches, benzodiazepines for agitation

Opioid Poisoning vs. Organophosphate Poisoning - Quick Comparison

Feature	Opioid	Organophosphate
Pupils	Pinpoint (miosis)	Pinpoint (miosis)
Secretions	Dry/normal	Copious (SLUDGE)
Bradycardia	Present	Present
Muscle fasciculations	Absent	Present
Garlic odor	Absent	Present
Antidote	Naloxone	Atropine + Pralidoxime
Response to naloxone	Dramatic reversal	No response

Mnemonic for opioid features: "3 Ms" - Miosis + Mental depression (unconsciousness) + Mild bradycardia/respiratory depression

Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry | Katzung's Basic and Clinical Pharmacology 16e | Tintinalli's Emergency Medicine | Goodman & Gilman's Pharmacological Basis of Therapeutics | Sabiston Textbook of Surgery

61a2efd6-19f2-4cb5-8038-bc33a212c6da.jpeg

aedac640-8169-4719-bba3-59a5d178261a.jpeg

Give MCQ all correct answer

Here are all 20 correct answers with brief explanations:

MCQ Answers - Pharmacology Pre-University Exam Paper I

1. C) Cromolyn sodium Cromolyn sodium is a mast cell stabilizer - it prevents attacks but has NO bronchodilator effect. It is useless in an acute attack. Salbutamol (SABA), hydrocortisone, and theophylline all have roles in acute management.

2. A) Tyrosine hydroxylase This is the rate-limiting step in catecholamine synthesis: Tyrosine → DOPA (tyrosine hydroxylase). This is the slowest/controlling step in the entire pathway.

3. C) Phenobarbital Phenobarbital is a long-acting barbiturate (t½ = 80-120 hours). Its long half-life means it accumulates with repeated dosing, causing cumulative and residual (hangover) effects. Triazolam and zolpidem are actually ultra-short acting.

4. A) Excreted faster in alkaline urine Weakly acidic drugs (e.g., aspirin, phenobarbital) are ionized in alkaline urine → ionized form cannot be reabsorbed → faster renal excretion. This is the principle behind urine alkalinization in salicylate poisoning.

5. B) Irreversibly inhibit cyclooxygenase by acetylation Aspirin acetylates the serine residue of COX-1 and COX-2 permanently. This is unique - all other NSAIDs are reversible competitive inhibitors of COX.

6. B) Blockade of voltage-gated sodium channels Local anesthetics (lidocaine, bupivacaine) block voltage-gated Na+ channels from inside the axon, preventing action potential propagation and nerve conduction.

7. D) Mivacurium Mivacurium is the only non-depolarizing blocker hydrolyzed by plasma pseudocholinesterase (like succinylcholine). It has a very short duration and does NOT need reversal with neostigmine.

8. A) Escitalopram Escitalopram is a pure SSRI. Imipramine = TCA; Venlafaxine = SNRI; Phenelzine = MAOI.

9. D) Glucuronidation Phase II (conjugation) reactions include glucuronidation, sulfation, acetylation, methylation, glycine conjugation. Oxidation, reduction, and hydrolysis are Phase I reactions.

10. B) Allopurinol Allopurinol is a xanthine oxidase inhibitor - it blocks conversion of hypoxanthine → xanthine → uric acid, reducing uric acid synthesis. Probenecid is uricosuric; colchicine is anti-inflammatory; indomethacin treats acute attacks.

11. B) Malignant hyperthermia The triad of muscle rigidity + hyperthermia + acidosis triggered by halothane (volatile anesthetic) ± succinylcholine = Malignant Hyperthermia. Caused by uncontrolled Ca²+ release from sarcoplasmic reticulum via RYR1 mutation. Treat with dantrolene.

12. B) Somatostatin Octreotide is a long-acting synthetic analogue of somatostatin. Used for acromegaly (suppresses GH), esophageal variceal bleeding, carcinoid syndrome, and VIPoma.

13. C) Crossing the blood-brain barrier First-generation antihistamines (e.g., diphenhydramine, chlorpheniramine) are lipophilic and readily cross the BBB, where they block central H1 receptors, causing sedation. Second-generation agents (cetirizine, loratadine) are poorly lipid-soluble and do NOT cross the BBB - hence non-sedating.

14. C) Dapagliflozin Dapagliflozin is an SGLT2 inhibitor - blocks glucose reabsorption in the proximal renal tubule → glucosuria → lowers blood glucose. Sitagliptin = DPP-4 inhibitor; Pioglitazone = thiazolidinedione; Liraglutide = GLP-1 agonist.

15. D) Levodopa Levodopa is used in Parkinson's disease, NOT bipolar disorder. Lithium, sodium valproate, and haloperidol (for mania) are all used in bipolar disorder.

16. B) Propylthiouracil (PTU) In the first trimester of pregnancy, PTU is preferred over carbimazole/methimazole because carbimazole is associated with aplasia cutis and choanal atresia (teratogenic). PTU has less placental transfer and does not carry these risks in the first trimester. (Note: From 2nd trimester onward, carbimazole may be switched back due to PTU's rare hepatotoxicity risk.) Radioactive iodine is absolutely contraindicated in pregnancy.

17. A) Highly lipid-soluble drugs Marked redistribution occurs with highly lipid-soluble drugs (e.g., thiopentone). After IV bolus, the drug rapidly distributes to the well-perfused brain (effect), then redistributes to muscle and fat (drug leaves the brain → effect terminates). This is why thiopentone has an ultra-short duration of action despite a long half-life.

18. B) Acute adrenal insufficiency Long-term high-dose corticosteroids suppress the HPA axis → adrenal cortical atrophy. Sudden withdrawal removes exogenous cortisol before the adrenal glands can recover → Addisonian crisis (acute adrenal insufficiency): hypotension, hyponatremia, hyperkalemia, hypoglycemia. This is why steroids must always be tapered gradually.

19. C) Oxytocin Oxytocin is the drug of choice for both prevention and treatment of postpartum hemorrhage (PPH). It causes uterine contraction, reducing bleeding. Terbutaline is a tocolytic (opposite effect - relaxes uterus). Magnesium sulfate is for eclampsia prophylaxis, not PPH.

20. C) Insulin glargine Insulin glargine (Lantus) has the longest duration of action (~24 hours, "peakless" basal insulin). Ranking: Glargine/Detemir > NPH > Regular > Lispro/Aspart/Glulisine (ultra-short).

Quick Reference Summary

Q	Answer	Key Word
1	C - Cromolyn sodium	Not useful in acute attack
2	A - Tyrosine hydroxylase	Rate-limiting step
3	C - Phenobarbital	Long t½ = accumulation
4	A - Excreted faster in alkaline urine	Ion trapping
5	B - Irreversible COX inhibition by acetylation	Aspirin unique feature
6	B - Voltage-gated Na+ channel blockade	Local anesthetic MOA
7	D - Mivacurium	Pseudocholinesterase hydrolysis
8	A - Escitalopram	SSRI
9	D - Glucuronidation	Phase II
10	B - Allopurinol	Xanthine oxidase inhibitor
11	B - Malignant hyperthermia	Rigidity + hyperthermia + halothane
12	B - Somatostatin	Octreotide analogue
13	C - Crossing BBB	1st gen sedation mechanism
14	C - Dapagliflozin	SGLT2 inhibitor
15	D - Levodopa	NOT used in bipolar
16	B - PTU	1st trimester hyperthyroidism
17	A - Highly lipid-soluble drugs	Redistribution
18	B - Acute adrenal insufficiency	Steroid withdrawal
19	C - Oxytocin	PPH drug of choice
20	C - Insulin glargine	Longest duration

This is a shared conversation. Sign in to Orris to start your own chat.